Intestinal Research

Original Articles

Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan: Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto; Received November 14, 2024 Accepted February 10, 2025 Published online March 20, 2025; DOI: https://doi.org/10.5217/ir.2024.00187 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Background/Aims
Tofacitinib and upadacitinib are small-molecule compounds that inhibit the Janus kinase pathway for the treatment of refractory ulcerative colitis. Only a few reports have compared the efficacy and safety of these 2 drugs in real-world practice. We aimed to show our real-world evidence of these drugs and compare the efficacy and safety profiles in the treatment of ulcerative colitis.
Methods
This study is a single-center retrospective analysis. Patients treated with tofacitinib or upadacitinib at our hospital between June 2018 and January 2024 who were monitored for 24 weeks were included. The primary outcome was steroid-free clinical remission at 24 weeks. Secondary outcomes were response and remission rates at each time point, time series changes in partial Mayo scores and laboratory results, treatment survival at 24 weeks, and the incidence of adverse events.
Results
A total of 68 patients treated with tofacitinib and 34 patients treated with upadacitinib were included. Steroid-free clinical remission rate at 24 weeks was significantly higher in upadacitinib-treated patients than in tofacitinibtreated patients (64.7% vs. 38.2%). The response rates in upadacitinib-treated patients exceeded 60% after 8 weeks of treatment through to 24 weeks, and the rates were higher than those in tofacitinib-treated patients. The incidences of adverse events were 79.4% in upadacitinib-treated patients and 38.2% in tofacitinib-treated patients. The most common adverse event was acne for upadacitinib.
Conclusions
Upadacitinib was more effective than tofacitinib in inducing remission in ulcerative colitis patients. The incidence of adverse events was significantly higher with upadacitinib than tofacitinib.

652 View
135 Download

IBD

Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study: Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto; Intest Res 2024;22(3):369-377. Published online July 16, 2024; DOI: https://doi.org/10.5217/ir.2023.00194

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of its short-term efficacy and safety profiles have already been published, reports of long-term real-world data have been limited. We aimed to show our 3-year evidence on the clinical use of tofacitinib for the treatment of UC, focusing on its efficacy and safety profiles.
Methods
A retrospective observational study was conducted on patients who started tofacitinib for active refractory UC at our hospital. The primary outcome was the retention rate until 156 weeks after initiating tofacitinib. The secondary outcomes were short-term efficacy at 4, 8, and 12 weeks; long-term efficacy at 52, 104, and 156 weeks; prognostic factors related to the cumulative retention rate; loss of response; and safety profile, including adverse events.
Results
Forty-six patients who were able to be monitored for up to 156 weeks after tofacitinib initiation, were enrolled in this study. Continuation of tofacitinib was possible until 156 weeks in 54.3%, with > 50% response rates and > 40% remission rates. Among patients in whom response or remission was achieved and tofacitinib was deescalated after 8 weeks of induction treatment, 54.3% experienced relapse but were successfully rescued by and retained on reinduction treatment, except for 1 patient. No serious AEs were observed in the study.
Conclusions
Tofacitinib is effective and safe as long-term treatment in a refractory cohort of UC patients in real-world clinical practice.

Citations

Citations to this article as recorded by

In which patients with ulcerative colitis would filgotinib be effective?
Jihye Park
Intestinal Research.2025; 23(1): 1. CrossRef
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
Rogério Serafim Parra, Renata de Sá Brito Fróes, Daniela Oliveira Magro, Sandro da Costa Ferreira, Munique Kurtz de Mello, Matheus Freitas Cardoso de Azevedo, Aderson Omar Mourão Cintra Damião, Alexandre de Sousa Carlos, Luísa Leite Barros, Maria Luiza Qu
BMC Gastroenterology.2025;[Epub] CrossRef

2,788 View
176 Download
2 Web of Science
2 Crossref

IBD

Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy: Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto; Intest Res 2024;22(1):65-74. Published online November 9, 2023; DOI: https://doi.org/10.5217/ir.2023.00092

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Endoscopic activity confirmed by enteroscopy is associated with poor clinical outcome in Crohn’s disease (CD). We investigated which of the existing biomarkers best reflects endoscopic activity in CD patients including the small bowel, and whether their combined use can improve accuracy.
Methods
One hundred and four consecutive patients with ileal and ileocolonic type CD who underwent balloon-assisted enteroscopy (BAE) from October 2021 to August 2022 were enrolled, with clinical and laboratory data prospectively collected and analyzed.
Results
Hemoglobin, platelet count, C-reactive protein, leucine-rich alpha-2 glycoprotein (LRG), fecal calprotectin, and fecal hemoglobin all showed significant difference in those with ulcers found on BAE. LRG and fecal calprotectin showed the highest areas under the curve (0.841 and 0.853) for detecting ulcers. LRG showed a sensitivity of 78% and specificity of 80% at a cutoff value of 13 μg/mL, whereas fecal calprotectin showed a sensitivity of 91% and specificity of 67% at a cutoff value of 151 μg/g. Dual positivity for LRG and fecal calprotectin, as well as LRG and fecal hemoglobin, both predicted ulcers with an improved specificity of 92% and 100%. A positive LRG or fecal calprotectin/hemoglobin showed an improved sensitivity of 96% and 91%. Positivity for LRG and either of the fecal biomarkers was associated with increased risk of hospitalization, surgery, and relapse.
Conclusions
The biomarkers LRG, fecal calprotectin, and fecal hemoglobin can serve as noninvasive and accurate tools for assessing activity in CD patients confirmed by BAE, especially when used in combination.

Citations

Citations to this article as recorded by

Leucine-rich alpha-2 glycoprotein in combination with C-reactive protein for predicting endoscopic activity in Crohn’s disease: a single-centre, cross-sectional study
Yoshiaki Takada, Hiroki Kiyohara, Yohei Mikami, Masataka Taguri, Ryoya Sakakibara, Yasuhiro Aoki, Kosaku Nanki, Takaaki Kawaguchi, Yusuke Yoshimatsu, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Naoki Hosoe, Haruhiko Ogata, Motohiko Kato, Yasushi
Annals of Medicine.2025;[Epub] CrossRef
Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
Masashi Ohno, Atsushi Nishida, Akinori Otsuki, Yoshihiro Yokota, Takayuki Imai, Shigeki Bamba, Osamu Inatomi
World Journal of Gastrointestinal Endoscopy.2025;[Epub] CrossRef
The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis
Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Behrad Saeedian, Tannaz Bagheri, Abdulrahman Ismaiel, Satohiro Matsumoto, Nastaran Babajani
European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn’s disease activity in the small bowel
Muneyori Okita, Kento Takenaka, Fumihito Hirai, Shinya Ashizuka, Hideki Iijima, Shigeki Bamba, Toshimitsu Fujii, Kenji Watanabe, Yosuke Shimodaira, Hisashi Shiga, Sakiko Hiraoka, Toshihiro Inokuchi, Takeshi Yamamura, Ryo Emoto, Shigeyuki Matsui
Journal of Gastroenterology.2025;[Epub] CrossRef
Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
Jihye Park
Intestinal Research.2024; 22(1): 1. CrossRef
Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn’s disease small bowel lesion in capsule endoscopy
Teppei Omori, Miki Koroku, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige
Intestinal Research.2024; 22(4): 464. CrossRef
Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease
Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kiz
Scientific Reports.2024;[Epub] CrossRef

4,234 View
310 Download
7 Web of Science
7 Crossref

Review

IBD

Artificial intelligence for endoscopy in inflammatory bowel disease: Kento Takenaka, Ami Kawamoto, Ryuichi Okamoto, Mamoru Watanabe, Kazuo Ohtsuka; Intest Res 2022;20(2):165-170. Published online January 7, 2022; DOI: https://doi.org/10.5217/ir.2021.00079

Abstract PDF PubReader ePub

Inflammatory bowel disease (IBD), with its 2 subtypes, Crohn’s disease and ulcerative colitis, is a complex chronic condition. A precise definition of disease activity and appropriate drug management greatly improve the clinical course while minimizing the risk or cost. Artificial intelligence (AI) has been used in several medical diseases or situations. Herein, we provide an overview of AI for endoscopy in IBD. We discuss how AI can improve clinical practice and how some components have already begun to shape our knowledge. There may be a time when we can use AI in clinical practice. As AI systems contribute to the exact diagnosis and treatment of human disease, we should continue to learn best practices in health care in the field of IBD.

Citations

Citations to this article as recorded by

Deep Learning Model Using Stool Pictures for Predicting Endoscopic Mucosal Inflammation in Patients With Ulcerative Colitis
Jung Won Lee, Dongwon Woo, Kyeong Ok Kim, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Ben Kang, Yoo Jin Lee, Jeongseok Kim, Byung Ik Jang, Eun Young Kim, Hyeong Ho Jo, Yun Jin Chung, Hanjun Ryu, Soo-Kyung Park, Dong-Il Park, Hosang Yu, Sungmoon Jeong
American Journal of Gastroenterology.2025; 120(1): 213. CrossRef
Could histologic healing be a new treatment target in patients with ulcerative colitis?
Soyoung Kim, Sang Hyoung Park
The Korean Journal of Internal Medicine.2024; 39(1): 2. CrossRef
From Data to Insights: How Is AI Revolutionizing Small-Bowel Endoscopy?
Joana Mota, Maria João Almeida, Francisco Mendes, Miguel Martins, Tiago Ribeiro, João Afonso, Pedro Cardoso, Helder Cardoso, Patrícia Andrade, João Ferreira, Miguel Mascarenhas, Guilherme Macedo
Diagnostics.2024; 14(3): 291. CrossRef
The Role of Artificial Intelligence in the Diagnosis and Treatment of Ulcerative Colitis
Petar Uchikov, Usman Khalid, Nikola Vankov, Maria Kraeva, Krasimir Kraev, Bozhidar Hristov, Milena Sandeva, Snezhanka Dragusheva, Dzhevdet Chakarov, Petko Petrov, Bistra Dobreva-Yatseva, Ivan Novakov
Diagnostics.2024; 14(10): 1004. CrossRef
Deep learning and minimally invasive inflammatory activity assessment: a proof-of-concept study for development and score correlation of a panendoscopy convolutional network
Pedro Cardoso, Miguel Mascarenhas, João Afonso, Tiago Ribeiro, Francisco Mendes, Miguel Martins, Patrícia Andrade, Hélder Cardoso, Miguel Mascarenhas Saraiva, João P.S. Ferreira, Guilherme Macedo
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
Knowledge, attitudes, and practices of endoscopy among gastroenterologists in diagnosis and management of inflammatory bowel disease in China: a multicenter cross-sectional study
Yinghao Sun, Gechong Ruan, Xiaoyin Bai, Wei Han, Minglan Yang, Lixin Jin, Yanni Huang, Xiaoxia Hou, Ke Shu, Yingying Liu, Yafeng Lu, Yan Zhao, Jie Zhong, Hong Yang
BMC Gastroenterology.2024;[Epub] CrossRef
Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events
Min Kyu Kim, Sung Wook Hwang
Clinical Endoscopy.2024; 57(6): 725. CrossRef
The pathobiology of follicular lymphoma
Joaquim Carreras
Journal of Clinical and Experimental Hematopathology.2023; 63(3): 152. CrossRef
Artificial Intelligence in Digestive Endoscopy—Where Are We and Where Are We Going?
Radu-Alexandru Vulpoi, Mihaela Luca, Adrian Ciobanu, Andrei Olteanu, Oana-Bogdana Barboi, Vasile Liviu Drug
Diagnostics.2022; 12(4): 927. CrossRef
Artificial intelligence within the small bowel: are we lagging behind?
Stefania Chetcuti Zammit, Reena Sidhu
Current Opinion in Gastroenterology.2022; 38(3): 307. CrossRef

5,703 View
421 Download
13 Web of Science
10 Crossref

Brief Communication

IBD

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis: Hiromichi Shimizu, Toshimitsu Fujii, Shuji Hibiya, Maiko Motobayashi, Kohei Suzuki, Kento Takenaka, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe; Intest Res 2021;19(1):115-118. Published online June 11, 2020; DOI: https://doi.org/10.5217/ir.2020.00030

PDF Supplementary Material PubReader ePub

Citations

Citations to this article as recorded by

Inflammatory bowel disease therapeutics: a bibliometric analysis of tofacitinib research in ulcerative colitis
Jianping Zhou, Yuting Xi, Yaping Zhang, Rui Zhang, Hao Fu, Ce Zhou
Frontiers in Pharmacology.2025;[Epub] CrossRef
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study
Sophie Vieujean, David Laharie, Anthony Buisson, Xavier Roblin, Mathurin Fumery, Stephane Nancey, Pauline Wils, Romain Altwegg, Laurence Seidel, Bénédicte Caron, Laurent Peyrin-Biroulet
Digestive and Liver Disease.2024; 56(4): 613. CrossRef
Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea
Young-Eun Kim, Ye-Jee Kim, Dae Hyun Jeong, Seonok Kim, Min Jee Kim, Hyeon Hwa Kim, Kyung-Wook Jo, Sang Hyoung Park, Seokchan Hong
Seminars in Arthritis and Rheumatism.2024; 65: 152362. CrossRef
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Pablo A. Olivera, Axel Dignass, Marla C. Dubinsky, Giovanni Peretto, Paulo G. Kotze, Iris Dotan, Taku Kobayashi, Subrata Ghosh, Fernando Magro, Jose Rocha Faria-Neto, Britta Siegmund, Silvio Danese, Laurent Peyrin-Biroulet
Digestive and Liver Disease.2024; 56(8): 1270. CrossRef
Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto
Intestinal Research.2024; 22(3): 369. CrossRef
Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study
Hyuk Yoon, Byong Duk Ye, Sang-Bum Kang, Kang-Moon Lee, Chang Hwan Choi, Joo-young Jo, Juwon Woo, Jae Hee Cheon
BMC Gastroenterology.2024;[Epub] CrossRef
Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies
Chien-Hung Lin, Wen-Sheng Liu, Chuan Wan, Hsin-Hui Wang
BMJ Open Gastroenterology.2024; 11(1): e001347. CrossRef
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
María Chaparro, Diana Acosta, Cristina Rodríguez, Francisco Mesonero, Miren Vicuña, Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Álvaro Hernández Martínez, Maite Arroyo, Isabel Vera, Alexandra Ruiz-Cerulla, Beatriz Sicilia, M. José Cabello Tapia, Ca
American Journal of Gastroenterology.2023; 118(7): 1237. CrossRef
Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, Stephane Zuily, Silvio Danese, Laurent Peyrin‐Biroulet
Alimentary Pharmacology & Therapeutics.2023; 57(11): 1231. CrossRef
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja
Expert Review of Gastroenterology & Hepatology.2022; 16(8): 737. CrossRef
Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef
Review article: guide to tofacitinib dosing in patients with ulcerative colitis
Peter M. Irving, Yvette Leung, Marla C. Dubinsky
Alimentary Pharmacology & Therapeutics.2022; 56(7): 1131. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
Effectiveness and Safety of Tofacitinib for Ulcerative Colitis
Vikas Taneja, Mohammed El-Dallal, Zadid Haq, Kartikeya Tripathi, Hannah K. Systrom, Linda F. Wang, Hyder Said, Paul A. Bain, Youlian Zhou, Joseph D. Feuerstein
Journal of Clinical Gastroenterology.2022; 56(10): e323. CrossRef
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
Laura A. Lucaciu, Nathan Constantine-Cooke, Nikolas Plevris, Spyros Siakavellas, Lauranne A.A.P. Derikx, Gareth-Rhys Jones, Charles W. Lees
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef

6,951 View
253 Download
19 Web of Science
16 Crossref

Reviews

Magnetic resonance enterography for the evaluation of the deep small intestine in Crohn's disease: Kazuo Ohtsuka, Kento Takenaka, Yoshio Kitazume, Toshimitsu Fujii, Katsuyoshi Matsuoka, Maiko Kimura, Takashi Nagaishi, Mamoru Watanabe; Intest Res 2016;14(2):120-126. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.120

Abstract PDF PubReader ePub

For the control of Crohn's disease (CD) a thorough assessment of the small intestine is essential; several modalities may be utilized, with cross-sectional imaging being important. Magnetic resonance (MR) enterography, i.e., MRE is recommended as a modality with the highest accuracy for CD lesions. MRE and MR enteroclysis are the two methods performed following distension of the small intestine. MRE has sensitivity and specificity comparable to computed tomography enterography (CTE); although images obtained using MRE are less clear compared with CTE, MRE does not expose the patient to radiation and is superior for soft-tissue contrast. Furthermore, it can assess not only static but also dynamic and functional imaging and reveals signs of CD, such as abscess, comb sign, fat edema, fistula, lymph node enhancement, less motility, mucosal lesions, stricture, and wall enhancement. Several indices of inflammatory changes and intestinal damage have been proposed for objective evaluation. Recently, diffusion-weighted imaging has been proposed, which does not need bowel preparation and contrast enhancement. Comprehension of the characteristics of MRE and other modalities is important for better management of CD.

Citations

Citations to this article as recorded by

Motility Mapping Quantification Using the Classical Optical Flow Algorithm for Small Bowel Crohn’s Disease: Comparison with Balloon-assisted Enteroscopy Findings
Yoshio Kitazume, Kento Takenaka, Kazuo Ohtsuka, Yasuo Ozawa, Koichiro Kimura, Ryosuke Watanabe, Junichi Tsuchiya, Toshimitsu Fujii, Masakazu Nagahori, Mamoru Watanabe, Ukihide Tateishi
Magnetic Resonance in Medical Sciences.2023; 22(3): 325. CrossRef
Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef
Magnetic Resonance Enterography and Capsule Endoscopy in Patients Undergoing Patency Capsule for the Evaluation of Small Bowel Crohn’s Disease: A Korean Clinical Experience
Hyun Seok Lee, Yun Jeong Lim, Jin-Hee Jung, Ji Hyung Nam, Junseok Park, Sun Hyung Kang, Ki Bae Kim, Hoon Jai Chun
Gastroenterology Research and Practice.2020; 2020: 1. CrossRef
Efficacy of Novel Ultrathin Single-Balloon Enteroscopy for Crohn’s Disease: A Propensity Score-Matched Study
Kaoru Takabayashi, Naoki Hosoe, Motohiko Kato, Yukie Hayashi, Ryoichi Miyanaga, Kosaku Nanki, Kayoko Fukuhara, Yohei Mikami, Shinta Mizuno, Tomohisa Sujino, Makoto Mutaguchi, Makoto Naganuma, Naohisa Yahagi, Haruhiko Ogata, Takanori Kanai
Gut and Liver.2020; 14(5): 619. CrossRef
High b-value computed diffusion-weighted imaging for differentiating bowel inflammation in Crohn's disease
Yoshio Kitazume, Junichi Tsuchiya, Kento Takenaka, Kazuo Ohtsuka, Koichiro Kimura, Ryosuke Watanabe, Tomoyuki Fujioka, Toshimitsu Fujii, Mamoru Watanabe, Ukihide Tateisi
European Journal of Radiology.2020; 133: 109362. CrossRef
The role of small bowel endoscopy for Crohn's disease
Stefania Chetcuti Zammit, Pierre Ellul, Reena Sidhu
Current Opinion in Gastroenterology.2019; 35(3): 223. CrossRef
Magnetic resonance enterography predicts the prognosis of Crohn's disease
Ji Hoon Lee, Yong Eun Park, Nieun Seo, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim, Joon Seok Lim, Jae Hee Cheon
Intestinal Research.2018; 16(3): 445. CrossRef
Quality Indicators for Small Bowel Capsule Endoscopy
Ki-Nam Shim, Seong Ran Jeon, Hyun Joo Jang, Jinsu Kim, Yun Jeong Lim, Kyeong Ok Kim, Hyun Joo Song, Hyun Seok Lee, Jae Jun Park, Ji Hyun Kim, Jaeyoung Chun, Soo Jung Park, Dong-Hoon Yang, Yang Won Min, Bora Keum, Bo-In Lee
Clinical Endoscopy.2017; 50(2): 148. CrossRef

7,316 View
74 Download
14 Web of Science
8 Crossref

Tacrolimus for the Treatment of Ulcerative Colitis: Katsuyoshi Matsuoka, Eiko Saito, Toshimitsu Fujii, Kento Takenaka, Maiko Kimura, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe; Intest Res 2015;13(3):219-226. Published online June 9, 2015; DOI: https://doi.org/10.5217/ir.2015.13.3.219

Abstract PDF PubReader

Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical response ranging from 61% to 96%. However, the long-term prognosis of patients treated with tacrolimus is disappointing, and almost 50% of patients eventually underwent colectomy in long-term follow-up. Tacrolimus can achieve mucosal healing in 40-50% of patients, and this is associated with a favorable long-term prognosis. Anti-tumor necrosis factor (TNF)-α antibodies are another therapeutic option in corticosteroid-refractory patients. A prospective head-to-head comparative study of tacrolimus and infliximab is currently being performed to determine which treatment is more effective in corticosteroid-refractory patients. Several retrospective studies have demonstrated that switching between tacrolimus and anti-TNF-α antibody therapy was effective in patients who were refractory to one of the treatments. Most adverse events of tacrolimus are mild; however, opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during treatment. Several issues on tacrolimus treatment in UC patients remain unsolved (e.g., use of tacrolimus as remission maintenance therapy). Further controlled studies are needed to optimize the use of tacrolimus for the treatment of UC.

Citations

Citations to this article as recorded by

Lactiplantibacillus plantarum ZJ316 Alleviates Helicobacter pylori-Induced Intestinal Inflammation by Sustaining Intestinal Homeostasis
Shiying Wu, Fangtong Wei, Yongqiang Chen, Ziqi Chen, Yuenuo Luo, Jiayi Fan, Yang Xu, Mingyang Hu, Ping Li, Qing Gu
Probiotics and Antimicrobial Proteins.2025;[Epub] CrossRef
Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study
Naoki Oshima, Sakiko Hiraoka, Ryohei Hayashi, Sakuma Takahashi, Manabu Ishii, Shinichi Hashimoto, Kazuo Yashima, Shoko Igawa, Toshihiro Inokuchi, Yoshitaka Ueno, Tomoki Inaba, Hiroshi Matsumoto, Kousaku Kawashima, Taro Takami, Hajime Isomoto, Akiko Shiota
Inflammatory Bowel Diseases.2024; 30(7): 1087. CrossRef
Exploring the therapeutic potential of Anastatica hierochuntica essential oil in DSS-induced colitis
Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Mohammed Alqudah, Muna Oqal, Rawan Abudalo, Shtaywy S. Abdalla
Inflammopharmacology.2024; 32(3): 2035. CrossRef
Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
Javier P Gisbert, María José García, María Chaparro
Journal of Crohn's and Colitis.2023; 17(6): 972. CrossRef
Gastrointestinal tract and viral pathogens
Gowthami Sai Kogilathota Jagirdhar, Yashwitha Sai Pulakurthi, Himaja Dutt Chigurupati, Salim Surani
World Journal of Virology.2023; 12(3): 136. CrossRef
Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection
Ting Xue, Xiaomei Kong, Liang Ma
Journal of Fungi.2023; 9(8): 812. CrossRef
Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
Florian Uellendahl-Werth, Carlo Maj, Oleg Borisov, Simonas Juzenas, Eike Matthias Wacker, Isabella Friis Jørgensen, Tim Alexander Steiert, Saptarshi Bej, Peter Krawitz, Per Hoffmann, Christoph Schramm, Olaf Wolkenhauer, Karina Banasik, Søren Brunak, Stefa
Communications Biology.2022;[Epub] CrossRef
Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA–PABA–MAC and 5-ASA–PABA–Diamine for the Treatment of Ulcerative Colitis
Jiaxing Zhao, Bing Zhang, Qing Mao, Kunqi Ping, Peng Zhang, Fengwei Lin, Dan Liu, Yao Feng, Ming Sun, Yan Zhang, Qiu Hua Li, Tingjian Zhang, Yanhua Mou, Shaojie Wang
Journal of Medicinal Chemistry.2022; 65(6): 4926. CrossRef
Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis
Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Mirela Pana, Rehab Gasiea, Gordon William Moran
Cochrane Database of Systematic Reviews.2022;[Epub] CrossRef
Combination tacrolimus and ustekinumab therapy is effective in inducing clinical, biochemical and endoscopic remission in refractory moderate to severe ulcerative colitis
Rachit Gupta, Julien D. Schulberg, Ola Niewiadomski, Emily K. Wright
Autoimmunity Reviews.2022; 21(7): 103115. CrossRef
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis
Sujaata Dwadasi, Maryam Zafer, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic
Inflammatory Bowel Diseases.2021; 27(10): 1620. CrossRef
Treatment of acute severe ulcerative colitis
Jun-Rong Li, Fang-Mei Ling, Yi-Dong Chen, Ming-Yang Xu, Liang-Ru Zhu
World Chinese Journal of Digestology.2021; 29(2): 87. CrossRef
Role of Topical Tacrolimus in the Management of Proctitis, Perianal Manifestations in Crohn's Disease, and Chronic Pouchitis: A Systematic Review
George Salem, Kai Ding, Atsushi Sakuraba, Russell Cohen
Journal of Investigative Medicine.2021; 69(4): 796. CrossRef
The Optimal Dose of Tacrolimus in Combination Therapy with an Anti-TNFα Antibody in a Mouse Colitis Model
Yuki Murakami, Mikihiro Fujiya, Hiroaki Konishi, Shotaro Isozaki, Yuya Sugiyama, Yu Kobayashi, Takahiro Sasaki, Takehito Kunogi, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura
Biological and Pharmaceutical Bulletin.2021; 44(4): 564. CrossRef
Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis
Roberto Manzini, Marlene Schwarzfischer, Kirstin Atrott, Andrea Laimbacher, Silvia Lang, Marcin Wawrzyniak, Andreas Rickenbacher, Matthias Turina, Petr Hruz, Donata Lissner, Britta Siegmund, Gerhard Rogler, Michael Scharl, Marianne R Spalinger
Inflammatory Bowel Diseases.2021; 27(12): 1986. CrossRef
The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin
PLOS ONE.2021; 16(4): e0250597. CrossRef
De Novo Inflammatory Bowel Disease Rarely Occurs During Posttransplant Immunosuppression
Jiayun M Fang, Laura Lamps, Amoah Yeboah-Korang, Jerome Cheng, Maria Westerhoff
American Journal of Clinical Pathology.2021; 156(6): 1113. CrossRef
Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis
Sara Hone Lopez, Gursah Kats-Ugurlu, Remco J. Renken, Henk J. Buikema, Marco R. de Groot, Marijn C. Visschedijk, Gerard Dijkstra, Mathilde Jalving, Jacco J. de Haan
Virchows Archiv.2021; 479(6): 1119. CrossRef
Protective effects of selenium in tacrolimus-induced lung toxicity: potential role of heme oxygenase 1
Salwa Abdel-Tawab Ibrahim, Nashwa Fathy Eltahawy, Ahlam Mohamed Abdalla, Hanaa Mohamed Khalaf
Canadian Journal of Physiology and Pharmacology.2021; 99(10): 1069. CrossRef
Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review
Biyu Wu, Jinglu Tong, Zhihua Ran
Inflammatory Bowel Diseases.2020; 26(1): 24. CrossRef
Simple water‐based tacrolimus enemas for refractory proctitis
Sasha R. Fehily, Felicity C. Martin, Michael A. Kamm
JGH Open.2020; 4(4): 561. CrossRef
Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody
Miki Kojima, Satoru Oji, Satoru Tanaka, Shoko Izaki, Baku Hashimoto, Hikoaki Fukaura, Kyoichi Nomura
Multiple Sclerosis and Related Disorders.2020; 39: 101907. CrossRef
Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis
Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Koki Okahara, Osamu Nomura, Dai Ishikawa, Naoto Sakamoto, Taro Osada, Akihito Nagahara
Journal of Clinical Medicine.2020; 9(6): 1771. CrossRef
Inflammatory Bowel Disease – Non-biological treatment
Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
Pharmacological Research.2020; 160: 105075. CrossRef
Lactobacillus plantarum L15 Alleviates Colitis by Inhibiting LPS-Mediated NF-κB Activation and Ameliorates DSS-Induced Gut Microbiota Dysbiosis
Peng Yu, Chuxin Ke, Jiaxin Guo, Xiuling Zhang, Bailiang Li
Frontiers in Immunology.2020;[Epub] CrossRef
3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease
Iria Seoane-Viaño, Noemí Gómez-Lado, Héctor Lázare-Iglesias, Xurxo García-Otero, José Ramón Antúnez-López, Álvaro Ruibal, Juan Jesús Varela-Correa, Pablo Aguiar, Abdul W. Basit, Francisco J. Otero-Espinar, Miguel González-Barcia, Alvaro Goyanes, Asteria L
Biomedicines.2020; 8(12): 563. CrossRef
A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
Kiyonori Kobayashi, Yasuo Suzuki, Kenji Watanabe, Kazunori Oda, Miyuki Mukae, Akihiro Yamada, Hirokazu Yamagami, Akira Nishimura, Hiroyuki Okamoto
The Journal of Clinical Pharmacology.2019; 59(2): 271. CrossRef
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease
Britt Christensen, Peter R. Gibson, Dejan Micic, Ruben J. Colman, Sarah R. Goeppinger, Olufemi Kassim, Andres Yarur, Christopher R. Weber, Russell D. Cohen, David T. Rubin
Clinical Gastroenterology and Hepatology.2019; 17(3): 486. CrossRef
The protective role of phloretin against dextran sulfate sodium-induced ulcerative colitis in mice
Zecai Zhang, Shan Li, Hongyang Cao, Peng Shen, Jiuxi Liu, Yunhe Fu, Yongguo Cao, Naisheng Zhang
Food & Function.2019; 10(1): 422. CrossRef
Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction
Yu Nishida, Shuhei Hosomi, Hirokazu Yamagami, Naoko Sugita, Shigehiro Itani, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara, Emiko Mizoguchi
PLOS ONE.2019; 14(3): e0213505. CrossRef
Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis
Peter Hoffmann, Cyrill Wehling, Johannes Krisam, Jan Pfeiffenberger, Nina Belling, Annika Gauss
World Journal of Gastroenterology.2019; 25(13): 1603. CrossRef
Advances in research of tacrolimus for treatment of inflammatory bowel disease
Jing-Jing Wang, Yi-Hong Fan
World Chinese Journal of Digestology.2019; 27(13): 842. CrossRef
Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling
Huining Fan, Wei Chen, Jinshui Zhu, Jing Zhang, Shiqiao Peng
International Immunopharmacology.2019; 76: 105909. CrossRef
Pharmacotherapy of ulcerative colitis – current status and emerging trends
Hilal Ahmad, Vijay L. Kumar
Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(6): 581. CrossRef
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef
Tacrolimus: An updated review on delivering strategies for multifarious diseases
Divya Dheer, Jyoti, Prem N. Gupta, Ravi Shankar
European Journal of Pharmaceutical Sciences.2018; 114: 217. CrossRef
Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
Yi-Juan Liu, Hua Fan, Wei-Wei Zhen, Xing Yu, Jin-Tong Chen, Cheng-Dang Wang
Medicine.2018; 97(32): e11440. CrossRef
Long-lasting Immunosuppressive Effects of tacrolimus-loaded Micelle NK61060 in Preclinical Arthritis and Colitis Models
Takamichi Sato, Junpei Konno, Akihiro Sekiguchi, Nao Yoneki, Kana Kawano, Tomohiro Hayashi, Yukina Ogawa, Aya Kikitsu, Takashi Aijima, Kazuhisa Hara, Shintaro Hara, Hitomi Hayashi, Kimiko Fuchigami, Naoko Igo, Yuki Takashima, Yuki Kobayashi, Masayuki Mori
Therapeutic Delivery.2018; 9(10): 711. CrossRef
In Vivo Study of the Efficacy of the Essential Oil of Zanthoxylum bungeanum Pericarp in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
Zecai Zhang, Peng Shen, Jiuxi Liu, Cong Gu, Xiaojie Lu, Yanxin Li, Yongguo Cao, Bo Liu, Yunhe Fu, Naisheng Zhang
Journal of Agricultural and Food Chemistry.2017; 65(16): 3311. CrossRef
Significant contribution of TRPC6 channel-mediated Ca²⁺ influx to the pathogenesis of Crohn’s disease fibrotic stenosis
Lin Hai Kurahara, Keizo Hiraishi, Miho Sumiyoshi, Mayumi Doi, Yaopeng Hu, Kunihiko Aoyagi, Yuwen Jian, Ryuji Inoue
Journal of Smooth Muscle Research.2016; 52: 78. CrossRef

10,588 View
109 Download
38 Web of Science
40 Crossref

First
Prev
Page of 1
Next
Last

Search